SEC Form 4 · accession 0001144204-17-043513
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Brian Piper
Officer — CFO and Corporate Secretary
Period of report
Aug 11, 2017
Accepted (ET)
Aug 15, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $1.32 | Aug 11, 2017 | A | 380,000 | A | — | Aug 11, 2027 | Common Stock | 380,000 | 380,000 | D |
Explanation of responses
- F1The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer.